Page 139 - 南京医科大学自然版

第46卷第9期 孟明辉，陈正新，王慧博. 翻译后修饰介导的膜表面稳态调控与胶质母细胞瘤免疫可见性重塑［J］.
2026年9月 南京医科大学学报（自然科学版），2026，46（9）：1398-1411 ·1409 ·

cer immune surveillance［J］. Nature，2018，553（7686）： ［41］MENG C Y，ZHANG H P，YI X W，et al. Reversal of tu⁃
91-95 mour immune evasion via enhanced MHC⁃Class⁃I antigen
［28］YU X F，LI W，LIU H D，et al. PD⁃L1 translocation to the presentation by a dual⁃functional RNA regulated system
plasma membrane enables tumor immune evasion through ［J］. Mol Cancer，2025，24（1）：258
MIB2 ubiquitination［J］. J Clin Invest，2023，133（3）： ［42］DEMEL U M ，BÖGER M ，YOUSEFIAN S ，et al. Acti⁃
e160456 vated SUMOylation restricts MHC class I antigen presen⁃
［29］CHOI S H，MANI M，KIM J，et al. DRG2 is required for tation to confer immune evasion in cancer［J］. J Clin In⁃
surface localization of PD⁃L1 and the efficacy of anti⁃PD⁃ vestig，2022，132（9）：e152383
1 therapy［J］. Cell Death Discov，2024，10（1）：260 ［43］LAUSS M，PHUNG B，BORCH T H，et al. Molecular pat⁃
［30］REN Y M，QIAN Y，AI L Y，et al. TRAPPC4 regulates terns of resistance to immune checkpoint blockade in mela⁃
the intracellular trafficking of PD⁃L1 and antitumor im⁃ noma［J］. Nat Commun，2024，15：3075
munity［J］. Nat Commun，2021，12（1）：5405 ［44］LIN W Z，CHEN L，ZHANG H J，et al. Tumor⁃intrinsic
［31］WANG H B，YAO H，LI C S，et al. HIP1R targets PD⁃L1 YTHDF1 drives immune evasion and resistance to im⁃
to lysosomal degradation to alter T cell⁃mediated cytotoxi mune checkpoint inhibitors via promoting MHC⁃I degra⁃
⁃city［J］. Nat Chem Biol，2019，15（1）：42-50 dation［J］. Nat Commun，2023，14（1）：265
［32］LONG Y R，CHEN R Q，YU X L，et al. Suppression of tu⁃ ［45］WU X Y，LI T H，JIANG R，et al. Targeting MHC⁃I mole⁃
mor or host intrinsic CMTM6 drives antitumor cytotoxicity cules for cancer：function，mechanism，and therapeutic
in a PD ⁃ L1 ⁃ independent manner［J］. Cancer Immunol prospects［J］. Mol Cancer，2023，22（1）：194
Res，2023，11（2）：241-260 ［46］JONGSMA M L M，DE WAARD A A，RAABEN M，et
［33］MIAO B P，HU Z Q，MEZZADRA R，et al. CMTM6 al. The SPPL3 ⁃ defined glycosphingolipid repertoire or⁃
shapes antitumor T cell response through modulating pro⁃ chestrates HLA class I⁃mediated immune responses［J］.
tein expression of CD58 and PD ⁃ L1［J］. Cancer Cell， Immunity，2021，54（1）：132-150
2023，41（10）：1817-1828 ［47］BUTT N S，KURDI M，FADUL M M，et al. Major histo⁃
［34］DU L Y，LEE J H，JIANG H F，et al. β⁃Catenin induces compatibility class⁃I（MHC⁃I）downregulation in glioblas⁃
transcriptional expression of PD⁃L1 to promote glioblasto⁃ toma is a poor prognostic factor but not a predictive indi⁃
ma immune evasion［J］. J Exp Med，2020，217（11）： cator for treatment failure［J］. Pathol Res Pract，2023，
e20191115 250：154816
［35］GUO M X，YUAN Z，JIN X，et al. Inhibition of ICAM1 di⁃ ［48］SINGH K，FOSTER M W，VIOLETTE M J，et al. A surgi⁃
minishes stemness and enhances antitumor immunity in cal window of opportunity trial evaluating the effect of the
glioblastoma via β⁃catenin/PD⁃L1 signaling［J］. Nat Com⁃ PCSK9 inhibitor evolocumab on tumoral MHC⁃I expres⁃
+
mun，2025，16（1）：8642 sion and CD8 infiltration in glioma［J］. Sci Rep，2025，
［36］JUNG M Y，AIBAIDULA A，BROWN D A，et al. Superin⁃ 15：37112
duction of immunosuppressive glioblastoma extracellular ［49］LI D Q，ZHANG Q，LI L，et al. β2⁃microglobulin main⁃
vesicles by IFN⁃γ through PD⁃L1 and IDO1［J］. Neuroon⁃ tains glioblastoma stem cells and induces M2⁃like polar⁃
col Adv，2022，4（1）：vdac017 ization of tumor⁃associated macrophages［J］. Cancer Res，
［37］SCHWEIGER M W，AMOOZGAR Z，REPITON P，et al. 2022，82（18）：3321-3334
Glioblastoma extracellular vesicles modulate immune PD⁃ ［50］BURSTER T，GÄRTNER F，BULACH C，et al. Regula⁃
L1 expression in accessory macrophages upon radiothera⁃ tion of MHC I molecules in glioblastoma cells and the sen⁃
py［J］. iScience，2024，27（2）：108807 sitizing of NK cells［J］. Pharmaceuticals，2021，14（3）：
［38］VESELY M D，ZHANG T X，CHEN L P. Resistance mech⁃ 236
anisms to anti⁃PD cancer immunotherapy［J］. Annu Rev ［51］LERNER E C，WORONIECKA K I，D’ANNIBALLE V
+
Immunol，2022，40：45-74 M，et al. CD8 T cells maintain killing of MHC⁃I⁃negative
［39］MAGGS L，SADAGOPAN A，MOGHADDAM A S，et al. tumor cells through the NKG2D ⁃ NKG2DL axis［J］. Nat
HLA class I antigen processing machinery defects in anti⁃ Cancer，2023，4（9）：1258-1272
tumor immunity and immunotherapy［J］. Trends Cancer， ［52］LIU Y E，WANG Y J，YANG Y R，et al. Emerging phago⁃
2021，7（12）：1089-1101 cytosis checkpoints in cancer immunotherapy［J］. Sig
［40］CHEN X F，LU Q，ZHOU H，et al. A membrane⁃associat⁃ Transduct Target Ther，2023，8：104
ed MHC⁃I inhibitory axis for cancer immune evasion［J］. ［53］HU J Y，DONG F，HE Y，et al. LRIG2 promotes glioblasto⁃
Cell，2023，186（18）：3903-3920 ma progression by modulating innate antitumor immunity